MEMENTO队列中血液生物标志物与认知及功能轨迹的关联
基于法国MEMENTO前瞻性队列1938名基线无痴呆的60岁以上个体,检测基线Aβ40/42、p-tau181和NfL,随访5年认知与功能变化。基线p-tau181和NfL较高与多数认知、躯体及功能结局下降更快相关,二者存在相乘交互;Aβ42/40比值较低仅与FCSRT和语义流畅性轻微加快下降相关。
要点
- 基线p-tau181和NfL较高与多数认知、躯体及功能结局下降更快相关。
- p-tau181与NfL对认知和功能轨迹恶化存在相乘关联。
- 较低的Aβ42/40比值仅与FCSRT和语义流畅性轻微加快下降相关。
核心结论
- 在记忆门诊样本中,p-tau181和NfL独立及联合地与更显著的认知、躯体和功能下降相关。
- AD血液生物标志物检测可能为理解高危个体认知、躯体和功能下降的生物学过程提供有用信息。
研究设计与样本
- 基于法国全国性MEMENTO队列的临床基础前瞻性研究,纳入基线无痴呆的60岁及以上个体。
- 共纳入1938名参与者,基线平均(SD)年龄72.8(6.6)岁,女性占62%。
- 基线使用Simoa HD-X分析仪检测β-淀粉样蛋白(Aβ)40和42、磷酸化tau(p-tau181)及神经丝轻链(NfL)浓度。
- MMSE、FCSRT、动物流畅性、连线测验A和B、SPPB及工具性日常生活活动能力每年评估一次,最长5年。
- 采用线性混合模型并校正潜在混杂因素,建模AD生物标志物与认知及功能下降的关系。
主要发现
- 基线p-tau181每增加1 SD与MMSE下降更快相关(β=-0.055,95%CI -0.067至-0.043),FCSRT(β=-0.034,95%CI -0.043至-0.025),流畅性(β=-0.029,95%CI -0.038至-0.020),SPPB(β=-0.040,95%CI -0.057至-0.022),4IADL(β=-0.115,95%CI 0.091至0.140)。
- 基线NfL每增加1 SD与MMSE下降更快相关(β=-0.039,95%CI -0.053至-0.025),FCSRT(β=-0.022,95%CI -0.032至-0.012),流畅性(β=-0.014,95%CI -0.024至-0.004),4IADL(β=0.077,95%CI 0.048至0.105)。
- p-tau181与NfL对认知和功能轨迹恶化存在相乘关联。
- 较低的Aβ42/40比值仅与FCSRT(每增加1 SD:β=0.011,95%CI 0.002至0.020)和语义流畅性(β=0.011,95%CI 0.003至0.020)轻微加快的认知下降相关。
- 上述关联未受APOE ε4、性别或教育水平修饰。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Elevated levels of Alzheimer disease (AD) blood-based biomarkers are associated with accelerated cognitive decline. However, their distinct relationships with specific cognitive and functional domains require further investigation. We aimed at estimating the associations between AD blood-based biomarkers and the trajectories of distinct cognitive and functional domains over a 5-year follow-up period. METHODS: We conducted a clinic-based prospective study using data from the MEMENTO study, a nationwide French cohort. We selected dementia-free individuals at baseline aged 60 years or older. Baseline measurements of β-amyloid (Aβ) 40 and 42, phosphorylated tau (p-tau181), and neurofilament light chain (NfL) concentrations were obtained using the Simoa HD-X analyzer. Mini-Mental State Examination (MMSE), Free and Cued Selective Reminding Test (FCSRT), animal fluency, Trail Making Tests A and B, Short Physical Performance Battery (SPPB), and Instrumental Activities of Daily Living were administered annually for up to 5 years. We used linear mixed models, adjusted for potential confounders, to model AD biomarkers' relation with cognitive and functional decline. RESULTS: A total of 1,938 participants were included in this study, with a mean (SD) baseline age of 72.8 (6.6) years, and 62% were women. Higher baseline p-tau181 and NfL were associated with significantly faster decline in most cognitive, physical, and functional outcomes (+1 SD p-tau181: βMMSE = -0.055, 95% CI -0.067 to -0.043, βFCSRT = -0.034, 95% CI -0.043 to -0.025, βfluency = -0.029, 95% CI -0.038 to -0.020, βSPPB = -0.040, 95% CI -0.057 to -0.022, and β4IADL = -0.115, 95% CI 0.091-0.140. +1 SD NfL: βMMSE = -0.039, 95% CI -0.053 to -0.025, βFCSRT = -0.022, 95% CI -0.032 to -0.012, βfluency = -0.014, 95% CI -0.024 to -0.004, and β4IADL = 0.077, 95% CI 0.048-0.105). A multiplicative association of p-tau181 and NfL with worsening cognitive and functional trajectories was evidenced. Lower Aβ42/40 ratio was only associated with slightly faster cognitive decline in FCSRT and semantic fluency (+1 SD: β = 0.011, 95% CI 0.002-0.020, and β = 0.011, 95% CI 0.003-0.020, respectively). These associations were not modified by APOE ε4, sex, nor education level. DISCUSSION: In a memory clinic sample, p-tau181 and NfL, both independently and jointly, are linked to more pronounced cognitive, physical and functional declines. Blood-based biomarker measurement in AD research may provide useful insights regarding biological processes underlying cognitive, physical, and functional declines in at-risk individuals.
引用
- Grasset L, Bouteloup V, Cacciamani F, et al. Associations Between Blood-Based Biomarkers and Cognitive and Functional Trajectories Among Participants of the MEMENTO Cohort. Neurology. 2024. PMID: 38626384. doi:10.1212/WNL.0000000000209307
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。